Haleon plc (HLN)
USD 9.71
(-2.02%)
USD 9.71
(-2.02%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 2.35 Billion GBP | 30.1% |
| 2022 | 2.18 Billion GBP | 10.87% |
| 2021 | 2.21 Billion GBP | 2.41% |
| 2020 | 1.91 Billion GBP | 61.99% |
| 2019 | 1.17 Billion GBP | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 677 Million GBP | 116.72% |
| 2024 Q2 | 505 Million GBP | -26.93% |
| 2023 Q4 | 305 Million GBP | -47.77% |
| 2023 FY | - GBP | 30.1% |
| 2023 Q3 | 584 Million GBP | 7.75% |
| 2023 Q2 | 542 Million GBP | -14.91% |
| 2023 Q1 | 637 Million GBP | 2.91% |
| 2022 Q3 | 576 Million GBP | 22.55% |
| 2022 Q1 | 473 Million GBP | 266.67% |
| 2022 Q4 | 619 Million GBP | 7.47% |
| 2022 FY | - GBP | 10.87% |
| 2022 Q2 | 470 Million GBP | -0.63% |
| 2021 Q2 | 453 Million GBP | -4.68% |
| 2021 Q3 | 511 Million GBP | 12.8% |
| 2021 Q4 | 129 Million GBP | -74.76% |
| 2021 Q1 | 475.25 Million GBP | 0.0% |
| 2021 FY | - GBP | 2.41% |
| 2020 FY | - GBP | 61.99% |
| 2019 FY | - GBP | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Amneal Pharmaceuticals, Inc. | 500.78 Million USD | -369.466% |
| Bausch Health Companies Inc. | 2.88 Billion USD | 18.51% |
| Catalent, Inc. | -284 Million USD | 927.817% |
| Emergent BioSolutions Inc. | -505.29 Million USD | 565.268% |
| Elanco Animal Health Incorporated | -224 Million USD | 1149.554% |
| Perrigo Company plc | 646.2 Million USD | -263.819% |
| Teva Pharmaceutical Industries Limited | 4.33 Billion USD | 45.742% |
| Zoetis Inc. | 3.68 Billion USD | 36.201% |